An in-depth analysis of the price changes and impact of dasatinib after it is included in medical insurance
From a therapeutic perspective, dasatinib is primarily targeted at adults with newly diagnosed chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), or Ph+ CML and Ph+ acute lymphoblastic leukemia (ALL) who no longer benefit from or are intolerant to other treatments. In addition, dasatinib is also an effective treatment option for children 1 year and older with chronic phase Ph+ CML and children 1 year and older with newly diagnosed Ph+ ALL and receiving chemotherapy.

As of March 2024, the original drug dasatinib has been launched in China and has successfully entered the Class B medical insurance list, bringing new treatment methods to many patients. Its price and medical insurance reimbursement policy have always been the focus of close attention by patients. At present, the drug mainly provides reimbursement treatment for patients who meet the indications. Common specifications of dasatinib on the market include 50 mg 60 tablets, 20 mg 60 tablets, etc. Each box is priced at about RMB 10,000. If the patient can be reimbursed through medical insurance, eligible patients can enjoy a certain degree of cost reduction, thereby reducing the financial burden. However, there may be differences in medical insurance policies in different regions, including reimbursement ratios, reimbursement conditions, etc. Therefore, when purchasing dasatinib, patients are advised to consult their local medical insurance agency or hospital.
It is understood that there are currently generic dasatinib drugs available overseas with more favorable prices. Common generic drug manufacturers include Indian pharmaceutical factories, Bangladesh pharmaceutical factories, etc. The ingredients of the generic drugs they produce are basically the same as those of the original drugs sold domestically and abroad. The price of similar specifications to the original drugs may be several hundred yuan (prices may fluctuate due to exchange rates).
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)